Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Compound Hit Analysis for MSD Patients to Investigate and Optimize Novel Therapies

Reference number
Coordinator Pixl Bio AB
Funding from Vinnova SEK 2 853 668
Project duration January 2026 - January 2029
Status Ongoing
Venture European Joint Programme on Rare Diseases
Call International collaborations with preclinical therapy studies of rare diseases

Purpose and goal

CHAMPION aims to develop therapies for Multiple Sulfatase Deficiency (MSD), a rare fatal neurodegenerative childhood disorder with no curative treatment. Building on screening of 5,632 compounds identifying 56 promising candidates. Goals: (1) validate compounds in vitro in cell models, (2) develop suitable formulations, (3) test efficacy in vivo in MSD mice, (4) establish PK/PD profiles, (5) elucidate mechanisms of action, and (6) evaluate potential for other lysosomal disorders.

Expected effects and result

The project expects to deliver at least one validated lead compound with demonstrated in vivo efficacy, suitable formulation and early PK/PD data, providing a foundation for future preclinical and clinical development. Additionally, expected to identify mechanisms of action, potential for orphan drug designation, and applicability to other sulfatase deficiencies and lysosomal disorders. The project may attract industry partners or public funding for continued development toward clinical trials.

Planned approach and implementation

The project comprises 6 experimental work packages (WP) over 36 months: WP1 validates 56 compounds in vitro in MSD cell models using phenomics, sulfatase activity and toxicity assays. WP2 develops formulations for selected candidates. WP3 tests efficacy in vivo in MSD mice. WP4 establishes PK/PD models. WP5 elucidates mechanisms of action via multi-omics. WP6 evaluates applicability to other lysosomal disorders. The consortium includes patient organization and regulatory/development expertise.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 July 2026

Reference number 2025-01793